Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026)

Regeneron Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $661.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 21.77% year-over-year to $661.6 million; the TTM figure through Mar 2026 stood at $4.4 billion (down 4.33% YoY), while the FY2025 annual figure was $4.6 billion, up 2.33% from the prior year.
• EBITDA was $661.6 million for Q1 2026 at Regeneron Pharmaceuticals, down from $853.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.5 billion in Q3 2025 to a low of $661.6 million in Q1 2026.
• Historically, EBITDA has averaged $1.1 billion across 5 years, with a median of $952.3 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA sank 74.23% in 2022, then surged 51.17% in 2024.
• A 5-year view of EBITDA shows it stood at $1.2 billion in 2022, then advanced by 1.79% to $1.3 billion in 2023, then slumped by 32.33% to $849.6 million in 2024, then advanced by 0.41% to $853.1 million in 2025, then fell by 22.45% to $661.6 million in 2026.
• The last three EBITDA figures came in at $661.6 million (Q1 2026), $853.1 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.